{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:36:32Z","timestamp":1774294592938,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00467-024-06622-z","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T04:03:30Z","timestamp":1735963410000},"page":"1635-1644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk factors and retreatment for relapse in childhood primary nephrotic syndrome treated with rituximab"],"prefix":"10.1007","volume":"40","author":[{"given":"Yuanzhao","family":"Zhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai W.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9680-1651","authenticated-orcid":false,"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2953-1924","authenticated-orcid":false,"given":"Jianjiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"6622_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(18)30536-1","journal-title":"Lancet"},{"key":"6622_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R, Bonilla-Felix M, Cano F, Christian M, Hahn D, Kang HG, Nakanishi K, Safouh H, Trachtman H, Xu H, Cook W, Vivarelli M, Haffner D (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877\u2013919. https:\/\/doi.org\/10.1007\/s00467-022-05739-3","journal-title":"Pediatr Nephrol"},{"key":"6622_CR3","doi-asserted-by":"publisher","unstructured":"Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM (2020) Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 4:CD2290. https:\/\/doi.org\/10.1002\/14651858.CD002290.pub5","DOI":"10.1002\/14651858.CD002290.pub5"},{"key":"6622_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/archdischild-2015-308924","volume":"101","author":"N Larkins","year":"2016","unstructured":"Larkins N, Kim S, Craig J, Hodson E (2016) Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Arch Dis Child 101:404\u2013408. https:\/\/doi.org\/10.1136\/archdischild-2015-308924","journal-title":"Arch Dis Child"},{"key":"6622_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1681\/ASN.2021111472","volume":"33","author":"EY Chan","year":"2022","unstructured":"Chan EY, Yu E, Angeletti A, Arslan Z, Basu B, Boyer O, Chan CY, Colucci M, Dorval G, Dossier C, Drovandi S, Ghiggeri GM, Gipson DS, Hamada R, Hogan J, Ishikura K, Kamei K, Kemper MJ, Ma AL, Parekh RS, Radhakrishnan S, Saini P, Shen Q, Sinha R, Subun C, Teo S, Vivarelli M, Webb H, Xu H, Yap HK, Tullus K (2022) Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33:1193\u20131207. https:\/\/doi.org\/10.1681\/ASN.2021111472","journal-title":"J Am Soc Nephrol"},{"key":"6622_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2215\/CJN.08570722","volume":"18","author":"EY Chan","year":"2023","unstructured":"Chan EY, Yap DY, Colucci M, Ma AL, Parekh RS, Tullus K (2023) Use of rituximab in childhood idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 18:533\u2013548. https:\/\/doi.org\/10.2215\/CJN.08570722","journal-title":"Clin J Am Soc Nephrol"},{"key":"6622_CR7","first-page":"109","volume":"1","author":"L Wang","year":"2021","unstructured":"Wang L, Hua R, Zhu Y, Lu Y, Gao H, Xia X, Zhang Q, Lu L, Deng F (2021) Single dose of rituximab in children with steroid-dependent \/ frequently relapsing nephrotic syndrome, Clinical Efficacy and Evaluation of Health-Related Quality of Life. Iran J Kidney Dis 1:109\u2013115","journal-title":"Iran J Kidney Dis"},{"key":"6622_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY Chan","year":"2020","unstructured":"Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, Yamamura T, Sinha A, Bagga A, Hogan J, Dossier C, Vivarelli M, Liu ID, Kamei K, Ishikura K, Saini P, Tullus K (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97:393\u2013401. https:\/\/doi.org\/10.1016\/j.kint.2019.09.033","journal-title":"Kidney Int"},{"key":"6622_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10157-016-1328-y","volume":"21","author":"S Fujinaga","year":"2017","unstructured":"Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T (2017) Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol 21:671\u2013676. https:\/\/doi.org\/10.1007\/s10157-016-1328-y","journal-title":"Clin Exp Nephrol"},{"key":"6622_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00467-015-3197-0","volume":"31","author":"K Kamei","year":"2016","unstructured":"Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S (2016) Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol 31:89\u201395. https:\/\/doi.org\/10.1007\/s00467-015-3197-0","journal-title":"Pediatr Nephrol"},{"key":"6622_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ndt\/gfac228","volume":"38","author":"A Sinha","year":"2023","unstructured":"Sinha A, Mathew G, Arushi A, Govindarajan S, Ghanapriya K, Grewal N, Rai K, Brijwal M, Kalluru SL, Tewari P, Misra A, Khandelwal P, Hari P, Bagga A (2023) Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects. Nephrol Dial Transplant 38:939\u2013949. https:\/\/doi.org\/10.1093\/ndt\/gfac228","journal-title":"Nephrol Dial Transplant"},{"key":"6622_CR12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Group KDIG","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"6622_CR13","doi-asserted-by":"publisher","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","volume":"97","author":"YH Ahn","year":"2018","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS, Ha IS, Cheong HI, Kim SY, Lee SJ, Kang HG (2018) Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine (Baltimore) 97:e13157. https:\/\/doi.org\/10.1097\/MD.0000000000013157","journal-title":"Medicine (Baltimore)"},{"key":"6622_CR14","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rava L, Ruggiero B, Emma F, Vivarelli M (2016) B Cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27:1811\u20131822. https:\/\/doi.org\/10.1681\/ASN.2015050523","journal-title":"J Am Soc Nephrol"},{"key":"6622_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","volume":"25","author":"S Fujinaga","year":"2010","unstructured":"Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K (2010) Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 25:539\u2013544. https:\/\/doi.org\/10.1007\/s00467-009-1377-5","journal-title":"Pediatr Nephrol"},{"key":"6622_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00467-018-4139-4","volume":"34","author":"JD Delbet","year":"2019","unstructured":"Delbet JD, Leclerc G, Ulinski T (2019) Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery? Pediatr Nephrol 34:529\u2013532. https:\/\/doi.org\/10.1007\/s00467-018-4139-4","journal-title":"Pediatr Nephrol"},{"key":"6622_CR17","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/ndt\/gfv355","volume":"31","author":"S Lovric","year":"2016","unstructured":"Lovric S, Ashraf S, Tan W, Hildebrandt F (2016) Genetic testing in steroid-resistant nephrotic syndrome: when and how? Nephrol Dial Transplant 31:1802\u20131813. https:\/\/doi.org\/10.1093\/ndt\/gfv355","journal-title":"Nephrol Dial Transplant"},{"key":"6622_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3389\/fped.2019.00377","volume":"7","author":"C Ling","year":"2019","unstructured":"Ling C, Wang X, Chen Z, Fan J, Meng Q, Zhou N, Sun Q, Hua L, Gui J, Liu X (2019) Altered B-lymphocyte homeostasis in idiopathic nephrotic syndrome. Front Pediatr 7:377. https:\/\/doi.org\/10.3389\/fped.2019.00377","journal-title":"Front Pediatr"},{"key":"6622_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1681\/ASN.2021050643","volume":"33","author":"K Iijima","year":"2022","unstructured":"Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K (2022) Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome. J Am Soc Nephrol 33:401\u2013419. https:\/\/doi.org\/10.1681\/ASN.2021050643","journal-title":"J Am Soc Nephrol"},{"key":"6622_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00467-020-04771-5","volume":"36","author":"M Okutsu","year":"2021","unstructured":"Okutsu M, Kamei K, Sato M, Kanamori T, Nishi K, Ishiwa S, Ogura M, Sako M, Ito S, Ishikura K (2021) Prophylactic rituximab administration in children with complicated nephrotic syndrome. Pediatr Nephrol 36:611\u2013619. https:\/\/doi.org\/10.1007\/s00467-020-04771-5","journal-title":"Pediatr Nephrol"},{"key":"6622_CR21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.clinthera.2023.03.002","volume":"45","author":"W Chen","year":"2023","unstructured":"Chen W, Cai J, Raffetseder U, Zhu B, Chen J, Song N, Li Y, Lu Y, Fang Y, Ding X, Wang J (2023) Association between high NK-cell count and remission of primary membranous nephropathy: a retrospective chart review and pilot study. Clin Ther 45:364\u2013374. https:\/\/doi.org\/10.1016\/j.clinthera.2023.03.002","journal-title":"Clin Ther"},{"key":"6622_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12882-022-03015-y","volume":"24","author":"Y Deng","year":"2023","unstructured":"Deng Y, Ou YY, Mo CJ, Huang L, Qin X, Li S (2023) Peripheral blood lymphocyte subsets in children with nephrotic syndrome: a retrospective analysis. BMC Nephrol 24:7. https:\/\/doi.org\/10.1186\/s12882-022-03015-y","journal-title":"BMC Nephrol"},{"key":"6622_CR23","doi-asserted-by":"publisher","first-page":"13083","DOI":"10.1038\/s41598-021-92573-6","volume":"11","author":"Q Ye","year":"2021","unstructured":"Ye Q, Zhou C, Li S, Wang J, Liu F, Liu Z, Mao J, Fu H (2021) The immune cell landscape of peripheral blood mononuclear cells from PNS patients. Sci Rep 11:13083. https:\/\/doi.org\/10.1038\/s41598-021-92573-6","journal-title":"Sci Rep"},{"key":"6622_CR24","doi-asserted-by":"publisher","first-page":"658562","DOI":"10.3389\/fimmu.2021.658562","volume":"12","author":"C Niu","year":"2021","unstructured":"Niu C, Chen Y, Li M, Zhu S, Zhou L, Xu D, Li Z, Xu J, Li W, Wang Y, Cui J (2021) Non-coated rituximab induces highly cytotoxic natural killer cells from peripheral blood mononuclear cells via autologous B cells. Front Immunol 12:658562. https:\/\/doi.org\/10.3389\/fimmu.2021.658562","journal-title":"Front Immunol"},{"key":"6622_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13075-016-1101-3","volume":"18","author":"W Merkt","year":"2016","unstructured":"Merkt W, Lorenz HM, Watzl C (2016) Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting. Arthritis Res Ther 18:206. https:\/\/doi.org\/10.1186\/s13075-016-1101-3","journal-title":"Arthritis Res Ther"},{"key":"6622_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.kint.2023.06.013","volume":"104","author":"M Colucci","year":"2023","unstructured":"Colucci M, Angeletti A, Zotta F, Carsetti R, Lugani F, Rava L, Ravani P, Emma F, Ghiggeri GM, Vivarelli M (2023) Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing\/steroid-dependent nephrotic syndrome. Kidney Int 104:577\u2013586. https:\/\/doi.org\/10.1016\/j.kint.2023.06.013","journal-title":"Kidney Int"},{"key":"6622_CR27","doi-asserted-by":"publisher","first-page":"726428","DOI":"10.3389\/fimmu.2021.726428","volume":"12","author":"M Fribourg","year":"2021","unstructured":"Fribourg M, Cioni M, Ghiggeri G, Cantarelli C, Leventhal JS, Budge K, Bin S, Riella LV, Colucci M, Vivarelli M, Angeletti A, Perin L, Cravedi P (2021) CyTOF-enabled analysis identifies class-switched B cells as the main lymphocyte subset associated with disease relapse in children with idiopathic nephrotic syndrome. Front Immunol 12:726428. https:\/\/doi.org\/10.3389\/fimmu.2021.726428","journal-title":"Front Immunol"},{"key":"6622_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000535010","volume":"55","author":"L Lan","year":"2024","unstructured":"Lan L, Lin Y, Yu B, Wang Y, Pan H, Wang H, Lou X, Lang X, Zhang Q, Jin L, Yang Y, Xiao L, Chen J, Han F (2024) Efficacy of rituximab for minimal change disease and focal segmental glomerulosclerosis with frequently relapsing or steroid-dependent nephrotic syndrome in adults: a Chinese multicenter retrospective study. Am J Nephrol 55:25\u201336. https:\/\/doi.org\/10.1159\/000535010","journal-title":"Am J Nephrol"},{"key":"6622_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/17843286.2016.1208955","volume":"72","author":"I Van Horebeek","year":"2017","unstructured":"Van Horebeek I, Knops N, Van Dyck M, Levtchenko E, Mekahli D (2017) Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature. Acta Clin Belg 72:147\u2013155. https:\/\/doi.org\/10.1080\/17843286.2016.1208955","journal-title":"Acta Clin Belg"},{"key":"6622_CR30","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","volume":"84","author":"P Ravani","year":"2013","unstructured":"Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84:1025\u20131033. https:\/\/doi.org\/10.1038\/ki.2013.211","journal-title":"Kidney Int"},{"key":"6622_CR31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","volume":"27","author":"AL Sellier-Leclerc","year":"2012","unstructured":"Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guerin V, Lapillonne H, Deschenes G, Ulinski T (2012) Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood\u2013follow-up after CD19 recovery. Nephrol Dial Transplant 27:1083\u20131089. https:\/\/doi.org\/10.1093\/ndt\/gfr405","journal-title":"Nephrol Dial Transplant"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06622-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06622-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06622-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:41:02Z","timestamp":1746099662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06622-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6622"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06622-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"18 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the First Affiliated Hospital Ethics Committee of Zhengzhou University (approval no. 2024-KY-0187\u2013001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}